🗞 We're thrilled to announce the launch of our new quarterly newsletter, designed to keep you at the forefront of AI-powered #pathology advancements. Stay up to date with the latest PathAI #digitalpathology innovations, announcements, publications, and more. Whether you're a pathologist, researcher, or simply passionate about the future of #medicine, our newsletter is your gateway to understanding how AI is revolutionizing pathology. Sign up: https://lnkd.in/ezFEqmeK #AI #biotech #MachineLearning #DeepLearning #Oncology #biotechnology
PathAI
Software Development
Boston, Massachusetts 51,596 followers
Improving patient outcomes with AI-powered pathology.
About us
PathAI's mission is to improve patient outcomes with AI-powered pathology. Our platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine learning. We are a company of diverse employees with a wide range of backgrounds and experiences. Our world class team is passionate about solving challenging problems and making a huge impact. Our office is located in the heart of Fenway. PathAI was recently voted one of BBJ's Best Places to Work!
- Website
-
http://www.pathai.com
External link for PathAI
- Industry
- Software Development
- Company size
- 501-1,000 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2016
- Specialties
- artificial intelligence, pathology, digital pathology, oncology, immuno-oncology, auto immune disease, neurodegenerative disease, companion diagnostics, precision medicine, solutions, R&D, computational pathology, deep learning, software engineering, AI, Machine Learning, IBD, and cancer research
Locations
-
Primary
Get directions
1325 Boylston St
Suite 10000
Boston, Massachusetts 02215, US
-
Get directions
3495 Hacks Cross Rd
Memphis, Tennessee 38125, US
Employees at PathAI
Updates
-
PathAI reposted this
Great writeup about our new paper from PathAI -- if you're interested in nuclear morphology and want to see it in action (beyond the paper figures), it's available to interact with via our demos on some example TCGA slides https://lnkd.in/ecetsUqr
Freelance Medical & Scientific Writer | Oncology, Immunotherapy, mRNA Therapeutics, Targeted Therapies | Genomics, Molecular Diagnostics, Biomedical Data Science | Biotech Product Marketing, Publications, Medical Affairs
Alterations in nucleus size, shape, and color are ubiquitous in cancer, but comprehensive quantification of nuclear morphology across a whole-slide histologic image remains challenging. A new open-access publication by John Abel and larger team at PathAI details the development of a pan-tissue, deep learning-based digital pathology pipeline for exhaustive nucleus detection, segmentation, and classification. I included the link to the full paper and a summary below for anyone interested. AI powered quantification of nuclear morphology in cancers enables prediction of genome instability and prognosis. https://lnkd.in/esNTTDjs Methods overview: The authors collected over 29,000 manual annotations of cell nuclei from H&E images of 21 tumor types and other diseases to train and validate an object detection and segmentation model. Their model for nucleus analysis is a Mask-RCNN-style architecture with a ResNet50 backbone pretrained on ImageNet. It was deployed on whole-slide H&E images from breast cancer (TCGA BRCA), lung adenocarcinoma (TCGA LUAD), and prostate adenocarcinoma (TCGA PRAD) cohorts. Following nuclear segmentation, the cell class of each nucleus was assigned using PathExplore models specific to each cancer type. Interpretable features describing the size, shape, stain intensity, and texture were computed for each individual nucleus. The mean and standard deviation of each feature for each cell class on each slide were used to summarize the nuclear morphology. Statistical analyses were performed to assess relationships between nuclear morphology and cancer type, genomic instability, breast cancer molecular subtype, survival, and gene expression. Results overview: The nuclear segmentation and classification model performed comparably to previously reported models. It revealed differences in nuclear morphology sufficient to distinguish between BRCA, LUAD, and PRAD. Cancer cell nuclear area was associated with increased aneuploidy score and homologous recombination deficiency across cancer types. It was also predictive of whole genome doubling. In the breast BRCA cohort, cell-type-specific nuclear morphology enabled classification of luminal A, basal-like, and HER2 molecular subtypes. Increased fibroblast nuclear area in BRCA was indicative of poor progression-free and overall survival and was associated with gene expression signatures related to extracellular matrix remodeling and anti-tumor immunity. In summary, this work highlights the power of machine learning-driven quantitative nuclear morphometry in multiple cancer types at scale. The models and resulting features have the potential to aid pathologists in discerning novel biomarkers and provide meaningful prognostic information for cancer patients.
-
-
🎆 Happy Independence Day from all of us at PathAI! 🎆 As we celebrate the 4th of July, we reflect on the freedoms we enjoy individually and as a collective, and how they enable the work we do. Thank you for partnering with us to innovate #pathology.
-
🔥 Kick off summer with a Fireside Chat on #DigitalPathology featuring our CEO, Andrew Beck! Join Andy and an incredible lineup of #GoogleCloud experts, partners, and customers at the Healthcare and Life Sciences Summer Camp. They'll dive into the latest #HealthTech #AI trends. https://lnkd.in/ecV5VK_R Sign up today to hear Andy’s discussion on July 24th at 1:00 PM ET to discover how PathAI is leveraging cutting-edge #AI technology to revolutionize #Pathology, #DrugDevelopment, #Oncology, #IBD, and #LiverDisease research.
-
This past week, we published our article, 𝐀𝐈 𝐩𝐨𝐰𝐞𝐫𝐞𝐝 𝐪𝐮𝐚𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐧𝐮𝐜𝐥𝐞𝐚𝐫 𝐦𝐨𝐫𝐩𝐡𝐨𝐥𝐨𝐠𝐲 𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫𝐬 𝐞𝐧𝐚𝐛𝐥𝐞𝐬 𝐩𝐫𝐞𝐝𝐢𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐠𝐞𝐧𝐨𝐦𝐞 𝐢𝐧𝐬𝐭𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐚𝐧𝐝 𝐩𝐫𝐨𝐠𝐧𝐨𝐬𝐢𝐬, in npj Precision Oncology where we describe the development of of a pan-tissue, #deeplearning based digital pathology pipeline for nucleus detection, segmentation, and classification enhancing nuclear morphologic #biomarker discovery. https://lnkd.in/eJwF_YZH Did you know that quantification of nuclear morphology is available as part of the PathExplore™ suite of algorithms? Here it is in action! Dive deep into nuclear morphology, cell & tissue segmentation, and more with PathExplore™ for #cancerresearch. Access our demo slides on our AISight® TxR platform so you can see all of the capabilities of AI-powered pathology has to offer: https://lnkd.in/eCn4xwj2 PathExplore™ is for research use only. Not for use in diagnostic procedures. #pathology #biotech #AI #biotechnology #oncology
-
Our recent manuscript published in 𝐧𝐩𝐣 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 details the development of our pan-tissue, AI-powered #digitalpathology pipeline for segmentation, identification, and classification of nuclear features directly from H&E whole-slide images. https://lnkd.in/eJwF_YZH A team of PathAI scientists led by John Abel utilized #deeplearning and trained PathExplore™ to dive deep into tumor biology, characterizing cell nuclei to help pathologists identify novel biomarkers, examine the relationship between nuclear morphology and genetic factors, and advance research into oncogenic transformation. Read more about the nuclear morphology and how researchers can utilize the PathExplore™ platform to expedite insights into #cancer biology, detection, and progression. #biotech #biotechnology #AI #pathology #oncology #deeplearning #machinelearning #cancerresearch PathExplore™ is for research use only. Not for use in diagnostic procedures.
-
We’re hiring! Our team is passionate about solving big challenges in #healthtech and transforming the field of #pathology with #artificialintelligence. We are looking for new team members to join us on our mission to improve patient outcomes & fuel #biopharma research. Our core values: -𝐏atients First We embody a patient first mindset with everything we do and are committed to meeting the needs of our customers to improve patient outcomes. -𝐀ccountability We set out to accomplish the tasks we commit to and take responsibility for our work, and our actions. -𝐓eam We are One PathAI, all working towards the same goal. We trust our teammates and count on each other to get the job done. -𝐇umility We know all that we do matters, big and small. We value openness, we are accepting of others, and are curious to learn from each other. -𝐀ll 𝐈n We are all passionate about our mission and our passion pushes us to be better every day. Apply today: https://lnkd.in/e8GArtha #Opentowork #hiring #leadership #softwareengineering #legal #biotechsales #biotech #biotechnology #newpositions
-
Our Chief Growth Officer, Nick Brown and Kristie Dolan, Senior VP and General Manager of Oncology and Pathology for Quest Diagnostics, were recently interviewed about the exciting ongoing #collaboration between PathAI and Quest Diagnostics and what it means for the future of #digitalpathology. https://lnkd.in/ggqy_q8g This strategic relationship marks a new era in digital pathology. PathAI will continue to support Quest through our cutting-edge AISightⓇ digital pathology image management system, enhancing the efficiency and quality of #pathology operations across the US. Our focus will remain on driving #innovation and advancing AI-powered solutions to improve patient outcomes and streamline healthcare delivery. Read more in the latest article to learn how our collaboration with Quest is set to transform the pathology landscape. #DigitalPathology #AI #Healthcare #HealthcareInnovation #QuestDiagnostics #Biotech #Biotechnology
-
PathAI reposted this
Cloud Technologist | Engineering Leader | Product Management | Data Analytics | AI/ML | Cloud Security | Inventor
Are you from the Health Care and Life Sciences (HCLS) industry ? Is your company exploring generative AI? It's a great opportunity to delve into HCLS innovations with generative AI on AWS. Join me and Dr Eric Walk MD, FCAP, chief medical officer from PathAI at AWS NewYork City Summit on July 10th for a breakout session on HCLS201- PathAI unlocks the next wave of precision medicine with generative AI. PathAI is a health technology company whose mission is to employ AI-powered pathology to enhance patient outcomes. It's a great opportunity to delve into how PathAI is actively advancing digital pathology through the use of generative AI. Thanks to Oiendrilla Das Stephanie Black-Dattoli (she/her) Ryan Greene Angella Mayr for bar-raising feedback on session structure and guidance. If you haven't registered for AWS NewYork City Summit 2024 yet, you can do so here: https://lnkd.in/eN_y2v43 #aws #awscloud #amazon #amazonwebservices #cloudcomputing #design #machinelearning #generativeai #AI #ml #GAI #GenerativeAI #aiadoption #AmazonBedrock #pathAI
-
-
Our Chief Medical Officer, Eric Walk MD, FCAP, was recently interviewed by Diagnostics World about the future of #AI and #pathology in #healthcare. https://lnkd.in/eg3m_QnS #Digitalpathology adoption is dramatically accelerating, with labs worldwide transitioning to fully digital workflows. This shift brings significant benefits, including faster analysis and advanced AI tools that enhance diagnostic accuracy and efficiency. However, it's essential to understand the different scenarios of digital and AI pathology integration, particularly for adopting Image Management Systems (IMS) to ensure seamless AI application and data management. Read more in the latest article featuring Dr. Eric Walk to explore how digital and AI solutions are transforming pathology labs and what decision-makers need to consider for successful adoption. #biotech #biotechnology #PathAI #healthcareinnovation